Compare Dishman Pharma with Cipla - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs CIPLA - Comparison Results

DISHMAN PHARMA     Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DISHMAN PHARMA CIPLA DISHMAN PHARMA/
CIPLA
 
P/E (TTM) x 25.1 24.7 101.7% View Chart
P/BV x 3.3 2.5 132.8% View Chart
Dividend Yield % 0.7 0.6 104.2%  

Financials

 DISHMAN PHARMA   CIPLA
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
CIPLA
Mar-19
DISHMAN PHARMA/
CIPLA
5-Yr Chart
Click to enlarge
High Rs374678 55.2%   
Low Rs129484 26.6%   
Sales per share (Unadj.) Rs197.8198.2 99.8%  
Earnings per share (Unadj.) Rs21.218.5 114.5%  
Cash flow per share (Unadj.) Rs34.735.0 99.2%  
Dividends per share (Unadj.) Rs2.003.00 66.7%  
Dividend yield (eoy) %0.80.5 153.9%  
Book value per share (Unadj.) Rs179.9186.3 96.5%  
Shares outstanding (eoy) m80.69805.70 10.0%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x1.32.9 43.4%   
Avg P/E ratio x11.931.4 37.8%  
P/CF ratio (eoy) x7.216.6 43.6%  
Price / Book Value ratio x1.43.1 44.9%  
Dividend payout %9.416.2 58.2%   
Avg Mkt Cap Rs m20,306468,031 4.3%   
No. of employees `0000.822.6 3.7%   
Total wages/salary Rs m5,35528,565 18.7%   
Avg. sales/employee Rs Th19,252.77,053.1 273.0%   
Avg. wages/employee Rs Th6,459.51,261.5 512.0%   
Avg. net profit/employee Rs Th2,064.1659.1 313.2%   
INCOME DATA
Net Sales Rs m15,961159,710 10.0%  
Other income Rs m2654,766 5.6%   
Total revenues Rs m16,226164,475 9.9%   
Gross profit Rs m4,10330,973 13.2%  
Depreciation Rs m1,09113,263 8.2%   
Interest Rs m9441,684 56.1%   
Profit before tax Rs m2,33420,791 11.2%   
Minority Interest Rs m0-172 0.0%   
Prior Period Items Rs m10-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m6245,695 10.9%   
Profit after tax Rs m1,71114,924 11.5%  
Gross profit margin %25.719.4 132.6%  
Effective tax rate %26.727.4 97.6%   
Net profit margin %10.79.3 114.7%  
BALANCE SHEET DATA
Current assets Rs m11,018124,266 8.9%   
Current liabilities Rs m9,51737,715 25.2%   
Net working cap to sales %9.454.2 17.4%  
Current ratio x1.23.3 35.1%  
Inventory Days Days11091 121.9%  
Debtors Days Days3595 36.7%  
Net fixed assets Rs m16,304105,190 15.5%   
Share capital Rs m1611,611 10.0%   
"Free" reserves Rs m12,907148,511 8.7%   
Net worth Rs m14,516150,123 9.7%   
Long term debt Rs m4,18938,301 10.9%   
Total assets Rs m29,805239,633 12.4%  
Interest coverage x3.513.3 26.0%   
Debt to equity ratio x0.30.3 113.1%  
Sales to assets ratio x0.50.7 80.3%   
Return on assets %8.96.9 128.5%  
Return on equity %11.89.9 118.6%  
Return on capital %17.511.8 148.1%  
Exports to sales %24.834.7 71.4%   
Imports to sales %3.70-   
Exports (fob) Rs m3,95655,419 7.1%   
Imports (cif) Rs m596NA-   
Fx inflow Rs m4,95257,410 8.6%   
Fx outflow Rs m69719,041 3.7%   
Net fx Rs m4,25538,368 11.1%   
CASH FLOW
From Operations Rs m2,78616,911 16.5%  
From Investments Rs m-1,529-16,687 9.2%  
From Financial Activity Rs m-941-3,487 27.0%  
Net Cashflow Rs m316-3,451 -9.2%  

Share Holding

Indian Promoters % 61.4 16.0 383.8%  
Foreign collaborators % 0.0 20.8 -  
Indian inst/Mut Fund % 3.7 12.2 30.3%  
FIIs % 12.7 23.7 53.6%  
ADR/GDR % 0.0 1.1 -  
Free float % 22.1 26.2 84.4%  
Shareholders   46,261 161,166 28.7%  
Pledged promoter(s) holding % 35.8 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DISHMAN PHARMA With:   VENUS REMEDIES  ORCHID PHARMA LTD  SANOFI INDIA  J.B.CHEMICALS  SHASUN PHARMA  

Compare DISHMAN PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 262 Points Lower; Oil & Gas and Banking Stocks Witness Selling(Closing)

Indian share markets witnessed negative trading activity throughout the day and ended lower. At the closing bell, the BSE Sensex stood lower by 262 points (down 0.7%).

Related Views on News

CIPLA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 9, 2019 | Updated on Sep 9, 2019

Here's an analysis of the annual report of CIPLA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.

CIPLA Announces Quarterly Results (1QFY20); Net Profit Up 5.6% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, CIPLA has posted a net profit of Rs 5 bn (up 5.6% YoY). Sales on the other hand came in at Rs 40 bn (up 1.3% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA Announces Quarterly Results (4QFY19); Net Profit Up 144.0% (Quarterly Result Update)

May 24, 2019 | Updated on May 24, 2019

For the quarter ended March 2019, CIPLA has posted a net profit of Rs 4 bn (up 144.0% YoY). Sales on the other hand came in at Rs 44 bn (up 19.1% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA Announces Quarterly Results (3QFY19); Net Profit Up 17.5% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, CIPLA has posted a net profit of Rs 3 bn (up 17.5% YoY). Sales on the other hand came in at Rs 40 bn (up 2.4% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA Announces Quarterly Results (2QFY19); Net Profit Down 15.8% (Quarterly Result Update)

Nov 12, 2018 | Updated on Nov 12, 2018

For the quarter ended September 2018, CIPLA has posted a net profit of Rs 4 bn (down 15.8% YoY). Sales on the other hand came in at Rs 40 bn (down 1.7% YoY). Read on for a complete analysis of CIPLA's quarterly results.

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Don't Buy Lakshmi Vilas Bank...Buy this Private Sector Bank with 74% Upside(The 5 Minute Wrapup)

Sep 4, 2019

Lakshmi Vilas Bank is in a vicious cycle. The stock is already down 57% in 2019. Despite this, the retail investors increased their holding.

Insider Buying Alert: Promoters Increase Stake in 8 High-Quality Smallcaps(Profit Hunter)

Sep 3, 2019

Insiders have increased their stakes in eight Hidden Treasure recommendations. Should you follow them?

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA 5-YR ANALYSIS

COMPARE DISHMAN PHARMA WITH

MARKET STATS